As preprinting shifts from niche practice to default first step in the publication pipeline, research offices are increasingly asked a deceptively simple question: which server should an author use? The bioRxiv vs medRxiv choice is the one that comes up most often, because the two platforms sit side by side in the life and health sciences yet operate under different screening rules and community expectations. Add Research Square’s multidisciplinary, journal-integrated model into the mix, and the decision has real consequences for timing, discoverability and compliance with funder and publisher policies.
This is not a trivial administrative detail. With NIH data-sharing enforcement now active, UKRI’s open access policy explicitly recognising preprints as a route to compliance, and cOAlition S continuing to encourage early dissemination, research administrators are the people authors turn to when a grant deadline, a REF output query, or a journal’s dual-submission policy collides with a preprint decision. Getting the venue right the first time avoids withdrawal-and-repost headaches later.
What Is bioRxiv? Scope and Screening for the Life Sciences
What is bioRxiv, in practical terms? Launched in 2013 by Cold Spring Harbor Laboratory (CSHL), bioRxiv is the default preprint server for biology, covering categories from genetics and neuroscience to ecology, bioinformatics and synthetic biology. It does not carry out peer review; instead, an in-house screening team checks submissions for plagiarism, non-scientific content and material that could raise dual-use or biosecurity concerns. That screening is deliberately lightweight — most manuscripts clear it within a few days — because the platform’s purpose is speed: getting findings into circulation before, or in parallel with, journal submission.
bioRxiv’s community norms reflect that speed-first design. Authors post early drafts, sometimes before all co-authors have signed off on final wording, and revise versions as review proceeds. Citation of bioRxiv preprints is now normalised across molecular and cell biology, and many journals in the space explicitly permit prior preprint posting, consistent with the ICMJE’s position that preprints are not considered duplicate publication.
medRxiv’s Extra Safeguards for Clinical and Public Health Research
medRxiv, launched in 2019 as a partnership between CSHL, Yale University and BMJ, exists precisely because health research carries a different risk profile. Findings about a treatment, a diagnostic tool or a public health intervention can influence clinical decisions or media coverage well before formal peer review has tested their validity — a risk that became impossible to ignore during the COVID-19 pandemic, when preprint clinical claims were repeatedly picked up by outlets without appropriate caveats.
Accordingly, medRxiv’s screening is more demanding than bioRxiv’s. Submissions are checked for evidence of ethical oversight — IRB or research ethics committee approval or an explicit exemption — and clinical trials must carry a registration ID from an ICMJE-recognised registry such as ClinicalTrials.gov. Screeners also check for material that could identify individual patients or participants. This typically extends the screening window to several days and sometimes longer where in-house queries to authors are needed. Every medRxiv preprint additionally carries a standard notice warning readers not to treat it as established clinical guidance and not to report on it in the media without expert review — a norm bioRxiv does not apply as prominently. COPE’s guidance on preprints reinforces this distinction: the ethical stakes of premature clinical dissemination are materially higher than for most basic-science findings.
Research Square: Multidisciplinary Reach and Journal-Integrated Preprinting
Research Square, founded in 2016 and acquired by Springer Nature in 2022, takes a third approach. Rather than specialising by discipline, it accepts preprints across all fields — chemistry, engineering, social sciences, humanities-adjacent research — and its distinguishing feature is In Review, a service used by more than a thousand participating journals. Authors can opt, at the point of journal submission, to have their manuscript automatically posted as a preprint carrying a Crossref DOI and a CC-BY 4.0 licence, with the posting timeline synchronised to the journal’s peer review process. If the paper is accepted, the preprint links through to the published version; if rejected, it remains on the platform with journal branding removed.
This integration changes the calculus for authors and administrators alike: the decision to preprint becomes a checkbox during submission rather than a separate deposit step, and the resulting record is archived in Portico for long-term preservation. The trade-off is that Research Square’s screening is a light “prescreen” rather than a discipline-specific ethics check, so it does not substitute for medRxiv’s clinical safeguards when the underlying research involves human subjects.
bioRxiv vs medRxiv: Community Norms, Screening Time and Choosing the Right Venue
Reduced to a single comparison, the bioRxiv vs medRxiv decision usually comes down to subject matter rather than preference. Laboratory-based biology, genomics, ecology and computational biology belong on bioRxiv, where the community expects rapid posting and light-touch screening. Anything involving patients, clinical trials, epidemiological data or public health interventions belongs on medRxiv, where the additional ethics and registry checks — and the accompanying reader caution notice — are the norm authors and readers now expect. Mixed-methods studies that straddle both (for example, a biomarker study with clinical trial data) are typically routed to medRxiv because of its subject-matter screening for human-participant research.
Research Square becomes the right answer when the target journal offers In Review, when the field falls outside strict biology or health sciences, or when an author wants preprinting handled automatically as part of submission rather than as a separate action. None of these three platforms competes on rigour of peer review — none of them performs peer review at all — so the choice is really about matching screening depth and community expectations to the sensitivity of the findings.
What This Means for Research Administrators
Research offices supporting authors through this decision should keep several practicalities in mind:
- Match the server to the risk profile, not just the discipline label — a biology-adjacent study with human data belongs on medRxiv, not bioRxiv, because of the ethics-approval and trial-registration checks.
- Advise on funder and REF implications separately. A preprint DOI is not automatically an eligible REF output; administrators should confirm that authors also deposit the accepted manuscript once peer review concludes.
- Check ORCID linkage at submission. All three platforms support ORCID iDs, and consistent linkage keeps the preprint, the eventual published article and institutional repository records connected via Crossref DOIs.
- Flag journal dual-submission policies early. Most major publishers now follow ICMJE guidance that preprints are not prior publication, but a minority of venues retain restrictions, so this is worth a five-minute check before posting.
- Treat CRediT contributor statements as part of the preprint record, not an afterthought. CASRAI originated the CRediT contributor role taxonomy in 2014, and the standard is now stewarded by NISO as ANSI/NISO Z39.104-2022; applying it consistently from preprint to final publication reduces later authorship disputes.
As preprint culture becomes the expected first step rather than an optional extra, the administrative burden shifts from “should we preprint” to “which server, and what compliance checks follow from that choice.” Institutions that build simple decision guidance — discipline, human-subjects status, target journal integration — into their researcher-facing documentation will spend less time untangling withdrawal requests and mismatched registry records later. The underlying standards bodies, from ICMJE to COPE to NISO, are converging on the same principle: preprints are a legitimate part of the scholarly record, provided the screening, registration and attribution practices around them are transparent and consistently applied.
Leave a Reply